Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
Status:
Completed
Trial end date:
2021-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and
pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in
dyslipidemic patients including familial hypercholesterolemia and severe
hypertriglyceridemia.